Do the results of the recently published PACIFIC trial shift decision making for patients with stage III NSCLC who are borderline surgical candidates?

Are you more now more likely to recommend definitive chemoradiotherapy + durvalumab in patients with borderline-resectable stage III NSCLC? http://www.nejm.org/doi/full/10.1056/NEJMoa1709937